» Articles » PMID: 34308401

Persistent SARS-CoV-2 Infectivity Greater Than 50 Days in a Case Series of Allogeneic Peripheral Blood Stem Cell Transplant Recipients

Overview
Specialty Oncology
Date 2021 Jul 26
PMID 34308401
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The coronavirus disease 19 (COVID-19) pandemic has infected tens of millions across the world, but there is a significant gap in our understanding about COVID-19 in the hematopoietic stem transplant (HSCT) recipient population. Prolonged viral shedding is frequently observed with severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), but studies suggest viral loads decline 10 days after symptom onset. Current CDC guidance suggests that severely ill and immunocompromised hosts are no longer infectious after 20 days from symptom onset. Cycle threshold (Ct) values are inversely proportional to the viral load and are used to detect SARS-CoV-2 RNA concentration. Specimens with reverse transcriptase PCR (RT-PCR) Ct values > 33-34 have been associated with inability to culture virus, and have been used as a surrogate for diminished infectivity. We report two cases of  allogeneic peripheral blood stem cell transplant (PBSCT) recipients who had prolonged durations of infectivity with SARSCov-2, based on culture positivity and persistently low Ct values for greater than 50 days.

Citing Articles

Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID-19 infection at an ambulatory cancer center.

Sanchez E, Krantz E, Yoke L, Gallaher M, Bhattacharyya P, So L Transpl Infect Dis. 2024; 26(1):e14223.

PMID: 38191852 PMC: 10922880. DOI: 10.1111/tid.14223.


Coronavirus Disease-2019 in the Immunocompromised Host.

Bertini Jr C, Khawaja F, Sheshadri A Clin Chest Med. 2023; 44(2):395-406.

PMID: 37085228 PMC: 9678818. DOI: 10.1016/j.ccm.2022.11.012.


Viral cultures, cycle threshold values and viral load estimation for assessing SARS-CoV-2 infectiousness in haematopoietic stem cell and solid organ transplant patients: a systematic review.

Jefferson T, Spencer E, Conly J, Rosca E, Maltoni S, Brassey J J Hosp Infect. 2022; 132:62-72.

PMID: 36473552 PMC: 9721162. DOI: 10.1016/j.jhin.2022.11.018.


Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

Nakaya Y, Nakashima Y, Harada N, Yamada K, Makuuchi Y, Kuno M J Infect Chemother. 2022; 29(2):223-227.

PMID: 36379403 PMC: 9659359. DOI: 10.1016/j.jiac.2022.10.020.


Correlation between Type I Interferon Associated Factors and COVID-19 Severity.

Bencze D, Fekete T, Pazmandi K Int J Mol Sci. 2022; 23(18).

PMID: 36142877 PMC: 9506204. DOI: 10.3390/ijms231810968.


References
1.
Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y . Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020; 71(15):793-798. PMC: 7184442. DOI: 10.1093/cid/ciaa345. View

2.
Beigel J, Tomashek K, Dodd L . Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply. N Engl J Med. 2020; 383(10):994. DOI: 10.1056/NEJMc2022236. View

3.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View

4.
Atkinson B, Petersen E . SARS-CoV-2 shedding and infectivity. Lancet. 2020; 395(10233):1339-1340. PMC: 7159877. DOI: 10.1016/S0140-6736(20)30868-0. View

5.
He X, Lau E, Wu P, Deng X, Wang J, Hao X . Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020; 26(5):672-675. DOI: 10.1038/s41591-020-0869-5. View